CD274 and acute myeloid leukemia: Compared to the rapid development of immunotherapies, especially checkpoint inhibitors using PD-1 and PD-L1 antibodies, in solid tumors, even with clear early scientific support of the PD-1-PD-LI pathway in the pathogenesis of AML, immunotherapy in AML has been lagging far behind solid tumors.